BCIQ Profiles

Company Profile ReportTarget Profile Report
0827 QTs
BioCentury & Getty Images

Product Development

Aug. 27 Quick Takes: BioMarin gains first worldwide approval for achondroplasia therapy

Plus: Roche’s Tecentriq withdrawal, a16z’s seed fund, Lynk’s venture round and more

Aug 28, 2021 | 12:00 AM GMT

The European Commission approved Voxzogo vosoritide from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to treat children with achondroplasia, marking the first approval worldwide for the CNP analog that inhibits FGFR3 signaling. BioMarin said the price in France

Read the full 682 word article

How to gain access

Continue reading with a
two-week free trial.